## Clinical Diagnosis and Management: MEN 2B with Medullary Thyroid Cancer ### Key Clinical Features **Key Point:** The patient has MEN 2B, characterized by: 1. **Medullary thyroid cancer (MTC)** — confirmed on FNA 2. **Mucosal neuromas** — lip and tongue nodules (pathognomonic for MEN 2B) 3. **RET M918T mutation** — the most aggressive RET mutation, associated with early-onset MTC and high metastatic risk ### MEN 2 Syndrome Classification | Feature | MEN 2A | MEN 2B | Familial MTC | |---------|--------|--------|---------------| | **Medullary thyroid cancer** | 100% | 100% | 100% | | **Pheochromocytoma** | 50% | 50% | Absent | | **Primary hyperparathyroidism** | 20–30% | <5% | Absent | | **Mucosal neuromas** | Absent | 100% | Absent | | **Marfanoid habitus** | Absent | Common | Absent | | **RET mutation** | Codon 634 (most common) | Codon 918 (M918T) | Various | | **Age at MTC onset** | 30–50 years | <20 years (often <10) | Variable | | **Aggressiveness** | Moderate | Very high | Variable | **High-Yield:** M918T is the most aggressive RET mutation. Patients with MEN 2B and M918T mutation have MTC that often presents in childhood and metastasizes early. Prophylactic total thyroidectomy is indicated in ALL RET-positive individuals, ideally before age 5 in MEN 2B. ### Why Total Thyroidectomy with Lymph Node Dissection Is Correct 1. **Confirmed medullary carcinoma** — MTC is an aggressive neuroendocrine malignancy with high metastatic potential. 2. **M918T mutation** — the most aggressive RET mutation; associated with early metastases and poor prognosis if not treated surgically. 3. **Mucosal neuromas (MEN 2B phenotype)** — indicates very high risk of aggressive MTC. 4. **Surgical cure is possible only with early total thyroidectomy** — partial thyroidectomy leaves residual disease in 50% of cases. 5. **Central compartment lymph node dissection** — MTC metastasizes early to central nodes; prophylactic dissection improves oncologic outcomes. **Clinical Pearl:** In MEN 2B with M918T mutation, total thyroidectomy should ideally be performed before age 5 (or as soon as the diagnosis is made). Even at age 32, surgery remains the standard of care and offers the best chance of cure if metastatic disease is absent. ### Why Other Options Are Wrong ```mermaid flowchart TD A[RET-positive patient with MTC]:::outcome --> B{Age at diagnosis?}:::decision B -->|Childhood/Young adult| C[Total thyroidectomy ASAP]:::action B -->|Adult with confirmed MTC| D[Total thyroidectomy + central dissection]:::action C --> E[Prophylactic surgery before metastases]:::outcome D --> E F[Observation or RAI]:::urgent --> G[Metastatic disease develops]:::urgent style G fill:#ffcccc ``` ### Management Algorithm for MEN 2B **Mnemonic — "CURE MTC in MEN 2B":** - **C**onfirm RET mutation (genetic testing) - **U**rgent total thyroidectomy (before age 5 if possible; at diagnosis if older) - **R**emove central and lateral lymph nodes (prophylactic dissection) - **E**valuate for pheochromocytoma (24-hour urine metanephrines) before surgery - **M**onitor calcitonin and CEA postoperatively - **T**reat metastatic disease (if present) with tyrosine kinase inhibitors (vandetanib, cabozantinib) - **C**ontinue surveillance (imaging, tumor markers) - **I**n MEN 2B: screen for mucosal neuromas and marfanoid features - **N**eck imaging (ultrasound, CT/MRI) to assess lymph node involvement **High-Yield:** Medullary thyroid cancer is the ONLY life-threatening malignancy in MEN 2B. Pheochromocytoma must be excluded (alpha-blockade given) before thyroidectomy to prevent intraoperative hypertensive crisis. ### Why Other Options Fail - **Option A (Thyroid hormone replacement + surveillance):** Observation is contraindicated in confirmed MTC. Watchful waiting leads to metastatic disease and death. - **Option C (Radioactive iodine):** RAI is ineffective for MTC because medullary carcinoma does not concentrate iodine (it arises from parafollicular C cells, not follicular cells). RAI is used for papillary and follicular thyroid cancers. - **Option D (Serial calcitonin + observation):** Delaying surgery in a young patient with aggressive M918T-driven MTC risks metastatic spread. Calcitonin monitoring is useful postoperatively but cannot replace surgery. [cite:Harrison 21e Ch 439; Robbins 10e Ch 24] 
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.